Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
20 February 2017
Answer given by Mr Andriukaitis on behalf of the Commission

1. Actions that will be developed under the future EU Action Plan against antimicrobial resistance (AMR) will be co-financed under a variety of EU funding programmes managed by the Commission, such as Horizon 2020(1), the Innovative Medicines Initiative(2) and the Common Financial Framework for the Food Chain and the Health Programme(3).2. The evaluation(4) of the 2011-2016 Commission Action Plan against AMR(5) has shown that this Plan provided the political stimulus for concrete actions within Member States, strengthened international cooperation and created a framework to guide and coordinate activities on AMR at national and global levels. This includes actions to strengthen the promotion of appropriate use of antimicrobials in both human and veterinary medicine for example through the development of guidelines, training, exchange of good practices and research.3. In 2017, the Commission will allocate EUR 1.7 million of the Common Financial Framework for the Food Chain to Member States for the monitoring of AMR in zoonotic bacteria in food and farmed animals. Some Member States and regions also intend to use European Regional Development Fund(6) allocations for health related investments, mainly for research and innovation, SME competitiveness, e-health and health infrastructures.


Last updated: 23 February 2017Legal notice